Meme kanserli 640 hastada hormon reseptör durumu ve C-erbB-2 düzeyi ile tedavi sonuçlari arasi iliski

Objective: In this study the relevant factors that effects the treatment outcomes of patients like hormone receptor and c-erbB-2 was established. Methods: The overall and disease-free survival rates were evaluated in 640 breast cancer patients. The mean follow-up was 59,1 months. Overall and disease-free survival rates found by Kaplan-Meier method at SPSS version 16.0. Log-Rank test evaluated the prognostic factors impact. Results: In ER (+) and (-) patients 5 year overall survival rates was 85,7%, 71,2% (p<0,001), disease free survival rates was 79,9%, 63,7% (p<0,001) respectively; in PR (+) and (-) patients 5 year overall survival rates was 85,6%, 71,6% (p<0,001), disease free survival rates was 79,6%, 64,3% (p<0,001) respectively. ER and PR positivity were significantly increased overall and disease-free survival. In c-erbB-2 over-expression 5 year overall survival rates was 76,4%, 85,3% (p=0,002), disease free survival rates was 69,7%, 79,1% (p=0,012) according to (-) patients. The worst prognosis had shown in ER (-), PR (-), cerbB- 2 (+) patients. Conclusion: ER, PR and c-erbB-2 levels have great importance in breast cancer and must be well considered in patients follow-up. © Copyright 2013 by Gazi University Medical Faculty

New inflammatory parameters in laryngopharyngeal reflux

PubMedID: 27499436Objectives: To investigate new inflammatory markers in patients with laryngopharyngeal reflux and determine whether these inflammatory parameters change in response to laryngopharyngeal reflux treatment. Methods: Complete blood count was evaluated to obtain platelet count and mean platelet volume and calculate neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio. Laryngopharyngeal reflux patients underwent three-month lansoprazole treatment. Results: The study included 45 laryngopharyngeal reflux patients (9 men (20 per cent); mean age, 37.4 ± 11.6 years) and 35 healthy age- and sex-matched controls (7 men (20 per cent); mean age, 38.6 ± 8.9 years). The study group had significantly higher platelet-to-lymphocyte ratios and lower mean platelet volumes than the control group (p = 0.004 and p = 0.047, respectively). There was a significant correlation between platelet-to-lymphocyte ratios and initial inflammatory symptoms (reflux symptom index, p = 0.025; reflux finding score, p = 0.013). There was also a significant correlation between mean platelet volume increase and symptom resolution in the first and third months of treatment (p = 0.04 and p = 0.03, respectively). Conclusion: Platelet-to-lymphocyte ratio, a new inflammatory marker of chronic inflammation, was significantly higher in laryngopharyngeal reflux patients. Moreover, these patients had significantly lower mean platelet volume values, which increased with post-treatment symptom improvement. Copyright © JLO (1984) Limited 2016

THE IMPRESSION WE GIVE TO PATIENTS WHEN BREAKING BAD NEWS: A MULTICENTER STUDY IN A TURKISH CANCER POPULATION

35th European-Society-for-Medical-Oncology (ESMO) Congress -- OCT 08-12, 2010 -- Milan, ITALYWOS: 000284592300403European Soc Med Onco

Postmastectomy RT Decision for Lymph Node Negative Patients: Turkish Radiation Oncology Society

37th Meeting of the European-Society-for-Radiotherapy-and-Oncology (ESTRO) -- APR 20-24, 2018 -- Barcelona, SPAINWOS: 000438676100060European Soc Radiotherapy & Onco

Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study

Purpose: To compare the incidence and severity of acute and chronic hematologic toxicity (HT) in patients treated with three-dimensional conformal radiotherapy (3DCRT) and intensity modulated radiotherapy (IMRT) for curative treatment of cervical cancer and to ascertain the dosimetric parameters of two techniques associated with acute and chronic HT. Materials and Methods: A total of 127 patients with cervical cancer receiving concomitant pelvic radiotherapy (RT) and cisplatin were evaluated. Pelvic bone marrow (BM) was contoured for each patient and divided into five sub-regions: lumbosacrum (LS), ilium (IL), lower pelvis (LP), pelvis (P), and whole pelvis (WP). The volume of each BM region receiving 10,20,30, and 40 Gy was calculated (V10, -V20, -V30, and -V40). The lowest level of hemoglobin, leukocyte, neutrophil, and platelet counts were obtained during chemoradiotherapy and six months after RT. The nadir values were graded according to Common Terminology Criteria for Adverse Events (version 3.0). Results: Grade 2 or greater acute anemia, leukopenia, neutropenia, thrombocytopenia was observed in 2%, 41.5%, 12%,and 0% in 3DCRT group and in 27%, 53%, 24.5%, and 4.5% in IMRT group, respectively. Grade 2 or greater chronic anemia, leukopenia, neutropenia, and thrombocytopenia was observed in 11%, 10%, 6%, and 0% in 3DCRT group and in 11%, 9%, 4.5%, and 0% in IMRT group, respectively. LS-V30,40; IL-V10,20,30,40; LP-V10,20,40; P-V10,20,30,40, and TP-V10,20,30,40 were significantly reduced with IMRT planning compared to 3DCRT planning. Logistic regression analysis of potential predictors showed that none of the dosimetric parameters were significant for predicting acute and chronic HT. Conclusion: The present findings showed that IMRT planning reduced irradiated BM volumes compared to 3DCRT planning. However, no difference between the two techniques was observed in terms of acute and chronic HT. Further studies are needed to confirm these results